Literature DB >> 21533869

Should we consider MMF therapy after rituximab for nephrotic syndrome?

Guido Filler1, Shih-Han Susan Huang, Ajay P Sharma.   

Abstract

The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21533869     DOI： 10.1007/s00467-011-1894-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  24 in total

1.  Severe respiratory adverse events associated with rituximab infusion.

Authors:  Koichi Kamei; Shuichi Ito; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-12-19       Impact factor: 3.714

2.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

3.  Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.

Authors:  Debbie S Gipson; Howard Trachtman; Frederick J Kaskel; Milena K Radeva; Jennifer Gassman; Tom H Greene; Marva M Moxey-Mims; Ronald J Hogg; Sandra L Watkins; Richard N Fine; John P Middleton; V M Vehaskari; Susan L Hogan; Suzzane Vento; Patti A Flynn; Leslie M Powell; June L McMahan; Norman Siegel; Aaron L Friedman
Journal:  Kidney Int       Date:  2010-12-22       Impact factor: 10.612

Review 4.  Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.

Authors:  Burkhard Tönshoff; Elias David-Neto; Robert Ettenger; Guido Filler; Teun van Gelder; Jens Goebel; Dirk R J Kuypers; Eileen Tsai; Alexander A Vinks; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Transplant Rev (Orlando)       Date:  2011-03-30       Impact factor: 3.943

5.  A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.

Authors:  K V Lieberman; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-01       Impact factor: 10.121

Review 6.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  E M Hodson; J F Knight; N S Willis; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 7.  To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

8.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

9.  Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil.

Authors:  Jutta Gellermann; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2004-01       Impact factor: 3.714

10.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.

Authors:  Vincent Guigonis; Aymeric Dallocchio; Véronique Baudouin; Maud Dehennault; Caroline Hachon-Le Camus; Mickael Afanetti; Jaap Groothoff; Brigitte Llanas; Patrick Niaudet; Hubert Nivet; Natacha Raynaud; Sophie Taque; Pierre Ronco; François Bouissou
Journal:  Pediatr Nephrol       Date:  2008-05-09       Impact factor: 3.714
View more
  10 in total

1.  Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.

Authors:  Maddalena Marasà; Paolo Cravedi; Barbara Ruggiero; Piero Ruggenenti
Journal:  BMJ Case Rep       Date:  2014-08-25

2.  Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.

Authors:  Kevin V Lemley; Robert H Mak
Journal:  Nat Rev Nephrol       Date:  2015-03-10       Impact factor: 28.314

3.  Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.

Authors:  Shuichiro Fujinaga; Tomonosuke Someya; Tsuneki Watanabe; Akira Ito; Yoshiyuki Ohtomo; Toshiaki Shimizu; Kazunari Kaneko
Journal:  Eur J Pediatr       Date:  2012-12-28       Impact factor: 3.183

4.  Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.

Authors:  Biswanath Basu; Anja Sander; Birendranath Roy; Stella Preussler; Shilpita Barua; T K S Mahapatra; Franz Schaefer
Journal:  JAMA Pediatr       Date:  2018-08-01       Impact factor: 16.193

5.  Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.

Authors:  Kazumoto Iijima; Mayumi Sako; Mari Oba; Seiji Tanaka; Riku Hamada; Tomoyuki Sakai; Yoko Ohwada; Takeshi Ninchoji; Tomohiko Yamamura; Hiroyuki Machida; Yuko Shima; Ryojiro Tanaka; Hiroshi Kaito; Yoshinori Araki; Tamaki Morohashi; Naonori Kumagai; Yoshimitsu Gotoh; Yohei Ikezumi; Takuo Kubota; Koichi Kamei; Naoya Fujita; Yasufumi Ohtsuka; Takayuki Okamoto; Takeshi Yamada; Eriko Tanaka; Masaki Shimizu; Tomoko Horinouchi; Akihide Konishi; Takashi Omori; Koichi Nakanishi; Kenji Ishikura; Shuichi Ito; Hidefumi Nakamura; Kandai Nozu
Journal:  J Am Soc Nephrol       Date:  2021-12-08       Impact factor: 10.121

6.  Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

Authors:  Stéphanie Tellier; Karine Brochard; Arnaud Garnier; Flavio Bandin; Brigitte Llanas; Vincent Guigonis; Mathilde Cailliez; Christine Pietrement; Olivier Dunand; Sylvie Nathanson; Aurélia Bertholet-Thomas; Lydia Ichay; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2013-01-23       Impact factor: 3.714

7.  Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.

Authors:  Julien Hogan; Claire Dossier; Thérésa Kwon; Marie-Alice Macher; Anne Maisin; Anne Couderc; Olivier Niel; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2018-08-14       Impact factor: 3.714

8.  Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.

Authors:  Abeer Yasin; Daisy Liu; Luan Chau; Joaquín Madrenas; Guido Filler
Journal:  BMC Nephrol       Date:  2013-02-17       Impact factor: 2.388

9.  Rituximab for Adults With Multi-Drug Resistant Focal Segmental Glomerulosclerosis: A Case Series and Review of the Literature.

Authors:  Ellia Zhong; Siavash Ghadiri; Alexander Pai; Judith G Marin; Sean J Barbour
Journal:  Can J Kidney Health Dis       Date:  2022-04-19

10.  Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).

Authors:  Tomoko Horinouchi; Mayumi Sako; Koichi Nakanishi; Kenji Ishikura; Shuichi Ito; Hidefumi Nakamura; Mari Saito Oba; Kandai Nozu; Kazumoto Iijima
Journal:  BMC Nephrol       Date:  2018-11-01       Impact factor: 2.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.